O	0	8	Patterns
O	9	11	of
B-intervention	12	16	HER2
I-intervention	17	24	testing
O	25	27	in
O	28	31	the
O	32	42	management
O	43	45	of
O	46	53	primary
O	54	60	breast
O	61	67	cancer
O	67	68	.

O	69	74	Women
O	75	79	with
O	80	88	invasive
O	89	95	breast
O	96	102	cancer
O	103	109	should
O	110	112	be
O	113	119	tested
O	120	123	for
O	124	129	human
O	130	139	epidermal
O	140	146	growth
O	147	153	factor
O	154	162	receptor
O	162	163	-
O	163	164	2
O	165	166	(
O	166	170	HER2
O	170	171	)
O	172	178	status
O	179	181	at
O	182	185	the
O	186	190	time
O	191	193	of
O	194	203	diagnosis
O	203	204	.

O	205	207	To
O	208	212	date
O	212	213	,
O	214	216	no
O	217	227	population
O	227	228	-
O	228	233	based
O	234	242	patterns
O	243	245	of
O	246	249	use
O	250	257	studies
O	258	262	have
O	263	271	examined
O	272	283	demographic
O	284	287	and
O	288	305	clinicopathologic
O	306	313	factors
O	314	324	associated
O	325	329	with
O	330	339	decisions
O	340	342	by
O	343	353	clinicians
O	354	356	to
O	357	361	test
O	362	370	patients
O	370	371	.

O	372	374	We
O	375	383	reviewed
O	384	391	summary
O	392	401	pathology
O	402	409	reports
O	410	419	submitted
O	420	422	to
O	423	426	the
B-location	427	438	Connecticut
O	439	444	Tumor
O	445	453	Registry
O	454	457	for
O	458	461	all
B-intervention	462	467	Black
I-intervention	467	468	/
I-intervention	468	475	African
I-intervention	476	484	American
O	485	486	(
O	486	487	B
O	487	488	/
O	488	490	AA
O	490	491	)
O	492	497	women
O	498	499	(
O	499	500	n
O	500	501	=
B-intervention-participants	501	504	644
O	504	505	)
O	506	509	and
O	510	511	a
O	512	513	7
O	513	514	%
O	515	521	random
O	522	528	sample
O	529	530	(
O	530	531	n
O	531	532	=
B-control-participants	532	535	720
O	535	536	)
O	537	539	of
B-control	540	545	White
B-eligibility	546	551	women
I-eligibility	552	561	diagnosed
I-eligibility	562	564	in
I-eligibility	565	569	2000
I-eligibility	569	570	-
I-eligibility	570	574	2003
I-eligibility	575	579	with
I-eligibility	580	587	primary
I-eligibility	588	596	invasive
I-eligibility	597	603	breast
I-eligibility	604	613	carcinoma
O	613	614	.

O	615	622	Receipt
O	623	625	of
O	626	627	a
O	628	632	HER2
O	633	637	test
O	638	639	(
O	639	642	yes
O	643	645	vs
O	645	646	.
O	647	649	no
O	649	650	)
O	651	654	was
O	655	663	examined
O	664	666	in
O	667	675	relation
O	676	678	to
O	679	686	patient
O	687	691	race
O	691	692	,
O	693	696	age
O	696	697	,
O	698	711	socioeconomic
O	712	718	status
O	718	719	,
O	720	724	year
O	725	727	of
O	728	737	diagnosis
O	737	738	,
O	739	747	estrogen
O	748	756	receptor
O	757	758	(
O	758	760	ER
O	760	761	)
O	762	768	status
O	768	769	,
O	770	775	tumor
O	776	781	grade
O	781	782	,
O	783	788	lymph
O	789	793	node
O	794	800	status
O	800	801	,
O	802	806	size
O	807	810	and
O	811	816	stage
O	817	819	at
O	820	829	diagnosis
O	829	830	.

O	831	832	A
O	833	840	greater
O	841	851	proportion
O	852	854	of
O	855	861	tumors
O	862	866	from
O	867	868	B
O	868	869	/
O	869	871	AA
O	872	880	patients
O	881	885	were
B-outcome	886	892	tested
O	893	901	compared
O	902	904	to
O	905	910	those
O	911	913	of
O	914	919	White
O	920	925	women
O	926	927	(
B-iv-bin-percent	927	929	69
I-iv-bin-percent	929	930	.
I-iv-bin-percent	930	931	5
I-iv-bin-percent	931	932	%
O	933	935	vs
O	935	936	.
B-cv-bin-percent	937	939	61
I-cv-bin-percent	939	940	.
I-cv-bin-percent	940	941	9
I-cv-bin-percent	941	942	%
O	942	943	,
O	944	945	p
O	945	946	<
O	946	947	0
O	947	948	.
O	948	950	05
O	950	951	)
O	951	952	.

O	953	959	Tumors
O	960	962	of
O	963	971	patients
O	972	977	under
O	978	981	the
O	982	985	age
O	986	988	of
O	989	991	60
O	992	996	were
O	997	998	1
O	998	999	.
O	999	1001	50
O	1001	1002	-
O	1002	1007	times
O	1008	1012	more
O	1013	1019	likely
O	1020	1024	than
O	1025	1030	older
O	1031	1036	women
O	1037	1039	to
O	1040	1044	have
O	1045	1049	been
O	1050	1056	tested
O	1056	1057	,
O	1058	1061	and
O	1062	1063	B
O	1063	1064	/
O	1064	1066	AA
O	1067	1072	women
O	1073	1077	were
O	1078	1079	1
O	1079	1080	.
O	1080	1082	40
O	1082	1083	-
O	1083	1088	times
O	1089	1093	more
O	1094	1100	likely
O	1101	1105	than
O	1106	1111	White
O	1112	1120	patients
O	1121	1123	to
O	1124	1126	be
O	1127	1133	tested
O	1133	1134	.

O	1135	1139	HER2
O	1140	1147	testing
O	1148	1151	was
O	1152	1156	more
O	1157	1163	likely
O	1164	1166	to
O	1167	1169	be
O	1170	1178	observed
O	1179	1183	when
O	1184	1195	information
O	1196	1200	also
O	1201	1204	was
O	1205	1213	reported
O	1214	1219	about
B-outcome	1220	1222	ER
I-outcome	1223	1229	status
O	1230	1231	(
O	1231	1233	OR
O	1233	1234	=
O	1234	1236	15
O	1236	1237	.
O	1237	1238	9
O	1238	1239	,
O	1240	1241	p
O	1241	1242	<
O	1242	1243	0
O	1243	1244	.
O	1244	1247	001
O	1247	1248	)
O	1248	1249	,
B-outcome	1250	1255	tumor
I-outcome	1256	1261	grade
O	1262	1263	(
O	1263	1265	OR
O	1265	1266	=
O	1266	1267	2
O	1267	1268	.
O	1268	1270	28
O	1270	1271	,
O	1272	1273	p
O	1273	1274	<
O	1274	1275	0
O	1275	1276	.
O	1276	1278	05
O	1278	1279	)
O	1279	1280	,
B-outcome	1281	1286	tumor
I-outcome	1287	1291	size
O	1292	1293	(
O	1293	1295	OR
O	1295	1296	=
O	1296	1297	2
O	1297	1298	.
O	1298	1300	16
O	1300	1301	,
O	1302	1303	p
O	1303	1304	<
O	1304	1305	0
O	1305	1306	.
O	1306	1308	05
O	1308	1309	)
O	1309	1310	,
O	1311	1314	and
B-outcome	1315	1320	lymph
I-outcome	1321	1325	node
I-outcome	1326	1332	status
O	1333	1334	(
O	1334	1336	OR
O	1336	1337	=
O	1337	1338	2
O	1338	1339	.
O	1339	1341	06
O	1341	1342	,
O	1343	1344	p
O	1344	1345	<
O	1345	1346	0
O	1346	1347	.
O	1347	1349	05
O	1349	1350	)
O	1350	1351	.

O	1352	1361	Variation
O	1362	1364	in
O	1365	1370	which
O	1371	1377	breast
O	1378	1384	cancer
O	1385	1393	patients
O	1394	1402	received
O	1403	1407	HER2
O	1408	1415	testing
O	1416	1423	appears
O	1424	1426	to
O	1427	1434	reflect
O	1435	1447	expectations
O	1448	1453	about
O	1454	1455	a
O	1456	1461	woman
O	1461	1462	'
O	1462	1463	s
O	1464	1473	prognosis
O	1473	1474	.

O	1475	1488	Discrepancies
O	1489	1491	in
O	1492	1499	receipt
O	1500	1502	of
O	1503	1510	testing
O	1511	1518	deserve
O	1519	1526	further
O	1527	1532	study
O	1533	1535	as
O	1536	1543	current
O	1544	1554	guidelines
O	1555	1559	call
O	1560	1563	for
O	1564	1567	all
O	1568	1574	tumors
O	1575	1577	to
O	1578	1580	be
O	1581	1589	assessed
O	1590	1592	in
O	1593	1598	order
O	1599	1601	to
O	1602	1612	adequately
O	1613	1625	characterize
O	1626	1635	prognosis
O	1636	1639	and
O	1640	1649	determine
O	1650	1661	eligibility
O	1662	1665	for
O	1666	1670	HER2
O	1670	1671	-
O	1671	1679	targeted
O	1680	1687	therapy
O	1687	1688	.
